| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.7 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.7 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.015 | 0.8 |